patent.fyi
Applications  /  US 2026/0356823
United States Patent Application Publication

US 2026/0356823 A1

Published
Nov 12, 2026
Filed
Aug 28, 2023
Earliest date on the face
Aug 28, 2022
Classification
C07D 405/12
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Four-membered fused carbocycle

What ifWhat if an ethylene bridge joined the two adjacent scaffold carbons to form a four-membered ring?
Claim language“a 5- to 7-membered ring”

The two bridge methylene units and the two shared scaffold carbons form a fused four-membered carbocycle. The shared edge fixes the relative positions of the two attachment sites, and the short bridge limits rotation between them.

1.3Sulfur-linked methyl group

What ifWhat if one Rb position carried a methylthio group?
Claim language“C1-C5 alkoxy”

A divalent sulfur atom connects the scaffold to a terminal methyl group through a C–S–C linkage. Sulfur retains the two-bond connection to the methyl group and increases the polarizability of the linkage.

1.4Eight-membered ring closure

What ifWhat if two Rb positions were joined through a tether that closed an eight-membered ring?
Claim language“a 3- to 7-membered ring”

At adjacent scaffold carbons, a six-methylene tether forms an eight-membered ring with the two attachment carbons. The tether keeps the attachment points connected while its internal single bonds permit several ring conformations.

1.5Dimethylsilicon ring junction

What ifWhat if a dimethylsilicon unit formed the two ring bonds at M1?
Claim language“C, O, S(═O)m, or N—Rn”

The silicon atom forms single bonds to both neighboring ring atoms and to two methyl groups. The four bonds give silicon a tetrahedral geometry and maintain a continuous ring path through M1.

1.9Ether-linked tertiary amine

What ifWhat if an Rc position carried a terminal dimethylamino group on an oxygen-containing spacer?
Claim language“C1-C5 alkyl NRc3Rc4”

An Rc substituent with the connectivity –O–CH₂–CH₂–N(CH₃)₂ uses an ether oxygen at the scaffold attachment and two methylene units before the terminal amine. The tertiary amine accepts a proton in aqueous solution, and the ether oxygen supplies a second hydrogen-bond acceptor in the neutral form.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Sulfoxide replaces a ring thioether

A formula I analogue uses S(═O) in place of thioether sulfur at M1, with M2 and the peripheral substituents held fixed. Controlled oxidation of the thioether gives the sulfoxide, which is separated from residual thioether and any sulfone by preparative chromatography. Where oxidation produces distinct sulfur stereoisomers, chiral chromatography separates them for individual Nav1.8 current measurements.

Parameter or scale variation

Seven membered ring at adjacent positions

A saturated seven-membered carbocycle shares the two adjacent carbon atoms that carry Ra1 and Ra2. A bridge of five methylene groups connects those atoms and supplies the other five members of the ring. Whole-cell voltage-clamp measurements compare the seven-membered analogue with a matched six-membered analogue that uses a four-methylene bridge.

Pulse frequency comparison for channel inhibition

A whole-cell voltage-clamp assay applies a fixed concentration of a formula I compound to mammalian cells expressing human Nav1.8. After equilibration, the instrument holds each cell at −90 mV and delivers a train of 20 pulses to +10 mV, each lasting 20 ms, at either 1 Hz or 10 Hz. Matched solvent-control cells receive the same pulse trains, and the ratio of the twentieth to the first peak current quantifies inhibition that accumulates during repetitive activation.

Combination with existing systems

Peripheral neuron assay with electrode arrays

A formula I test compound is integrated into a multiwell microelectrode array assay containing human stem-cell-derived sensory neurons. Each well contains neurons cultured over recording electrodes, and paired wells receive the compound or its solvent. The array records spontaneous firing and electrically evoked spike counts before and after dosing. Parallel voltage-clamp measurements in cells expressing Nav1.8 provide a separate channel-current readout.

Automated or data-driven variant

Automated concentration response fitting

A liquid handler prepares an eight-point, threefold dilution series of a formula I compound and transfers it to an automated patch-clamp plate containing Nav1.8-expressing cells. The instrument records baseline and post-dose peak inward currents using the same voltage protocol. Software excludes wells that fail preset seal-resistance or baseline-stability criteria, normalizes the current data against solvent controls, and fits a concentration-response curve to estimate the half-maximal inhibitory concentration.

Specific version of a part

Six-membered oxygen heterocycle

A saturated six-membered heterocycle contains one endocyclic oxygen atom and five carbon atoms. The oxygen forms single bonds to its two neighboring carbons and serves as a hydrogen-bond acceptor.

Endocyclic carbonyl at X3

X3 is a carbonyl carbon with single bonds to the two neighboring ring carbons. Its oxygen projects outside the ring and provides a hydrogen-bond acceptor.

Six-membered cyclic tertiary amine

Rc3 and Rc4 form a five-methylene bridge between the two substituent bonds on their shared nitrogen. The nitrogen completes a saturated six-membered ring and carries the bond to the rest of the molecule.

Ring sulfur with two oxo groups

The value of m is 2 at an S(═O)m ring position. The sulfur bonds to both neighboring ring atoms and bears two exocyclic oxo groups.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 11,339,152 B2
Published
May 24, 2022
Filed
Apr 3, 2018
Class
C07D 417/12
Document BUS 2022/0259201 A1
Published
Aug 18, 2022
Filed
May 14, 2020
Class
C07D 471/04
Claim 1
Document A
Document B
1.1Ra1, Ra2, and Ra are each independently selected from hydrogen, halogen, hydroxyl, C1-C5 alkyl, C1-C5 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkoxy, or —N(Rc3Rc4)m, or any adjacent two of Ra1, Ra2, and Ra3 are linked together to form a 5- to 7-membered ring, the 5- to 7-membered ring is a saturated or unsaturated carbocyclic or heterocyclic ring
Substituents for aryl and heteroaryl are selected from C1-6 alkyl (e.g. methyl), C2-6 alkenyl (e.g. buten-3-yl), C2-6 alkynyl (e.g. butyn-3-yl), C1-6 haloalkyl (e.g. fluoromethyl, trifluoromethyl), —C1-6 thioalkyl (e.g. —S-methyl), —SOC1-4 alkyl (e.g. —SOmethyl), —SO2C1-4 alkyl (e.g. —SO2methyl), C1-6 alkoxy-(e.g. methoxy, ethoxy), —O—C3-8 cycloalkyl (e.g. —O-cyclopentyl or —O-cyclohexyl), C3-8 cycloalkyl (e.g. cyclopropyl, cyclohexyl), —SO2C3-8 cycloalkyl (e.g. —SO2cyclohexy
A · US 11,339,152 B2 · ¶ 82
or, any two adjacent or non-adjacent R3 are connected to form a cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted by one or more substituents selected from hydrogen, deuterium, substituted or unsubstituted alkyl, substituted or unsubstituted deuterated alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, halogen, amin
B · US 2022/0259201 A1 · ¶ 17
1.2the heterocyclic ring optionally contains one or more N, O, or S(═O)m heteroatoms
The expression “heterocyclyl”, unless specifically limited, refers to a carbocyclyl group wherein one or more (e.g. 1, 2 or 3) ring atoms are replaced by heteroatoms selected from N, S and O. A specific example of a heterocyclyl group is a cycloalkyl group (e.g. cyclopentyl or more particularly cyclohexyl) wherein one or more (e.g. 1, 2 or 3, particularly 1 or 2, especially 1) ring atoms are replaced by heteroatoms selected from N, S or O.
A · US 11,339,152 B2 · ¶ 33
The term “heterocyclyl” refers to saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent comprising 3 to 20 ring atoms, wherein one or more of the ring atoms are heteroatoms selected from nitrogen, oxygen, C(O), S(O)(═NH) or S(O)m (wherein m is an integer of 0 to 2), but not including the ring part of —O—O—, —O—S— or —S—S—, and the remaining ring atoms are carbon.
B · US 2022/0259201 A1 · ¶ 274
1.3Rb1, Rb2, Rb3, and Rb4 are each independently selected from hydrogen, halogen, hydroxyl, C1-C5 alkyl, or C1-C5 alkoxy
Specific substituents that may be mentioned are one or more e.g. 1, 2 or 3 groups selected from halogen, hydroxyl, alkyl (e.g. methyl) and alkoxy-(e.g. methoxy-).
A · US 11,339,152 B2 · ¶ 84
Raa, Rbb, Rcc, Rdd and Ree are each independently selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, cyano, nitro, hydroxyl, amino, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally further substituted by one or more substituents selected from hydrogen, deuterium, subst
B · US 2022/0259201 A1 · ¶ 20
1.4or any two of Rb1, Rb2, Rb3, and Rb4 are linked together to form a 3- to 7-membered ring
or, any two of Raa, Rbb and Rcc are optionally connected to form a C3-8 cycloalkyl or a 3-12 membered heterocyclyl, wherein the C3-8 cycloalkyl and 3-12 membered heterocyclyl are optionally further substituted by one or more substituents selected from hydrogen, amino, halogen, cyano, hydroxyl, oxo, imino, C1-6 alkyl or C1-6 hydroxyalkyl;
B · US 2022/0259201 A1 · ¶ 133
1.5M1 and M2 are each independently selected from C, O, S(═O)m, or N—Rn, where Rn is optionally selected from hydrogen or C1-C5 alkyl
Y1, Y2, Y3 and Y4 are independently selected from CH, N, S and O;
A · US 11,339,152 B2 · claim 3
1.6a ring A is A1 or A2: optionally represents a single bond or a double bond
1.7X1, X2, X3, X4, and X5 are each independently selected from a bond, C, N, O, C═O, or S(═O)m
A compound represented by general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: wherein: X1-X6 are each independently selected from C, N, CR5, CRaaRbb or NRaa;
B · US 2022/0259201 A1 · claim 1
1.8Y1 and Y2 are the same or different, and are each optionally selected from a C atom or a N atom
1.9Rc1 and Rc2 are each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, C1-C5 alkyl, C1-C5 alkoxy, —S(═O)m—Rc3Rc4, —C(═O)—NRc3Rc4, —C(═S)—NRc3Rc4, —N(Rc3Rc4)m, —P(═O)m—Rc3Rc4, —C(═N)—NRc3Rc4, —S(═O)2NRc3Rc4, —C1-C5 alkyl NRc3Rc4, or —S(═O)(═NRc3)Rc4
D is selected from aryl-amino, heteroaryl-amino, cycloalkyl-amino, heterocyclyl, heterocyclyl-amino, urea, thioamide, thiourea, sulfonamide and sulfoximine, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted with one or more substituents;
A · US 11,339,152 B2 · ¶ 66
R1 is selected from hydrogen, deuterium, alkyl, deuterated alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, amino, nitro, hydroxyl, cyano, oxo, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, —(CH2)n1Raa, —(C≡C)n1(CRaaRbb)mRcc, —(C═C)n1(CRaaRbb)mRcc, —(CH2)n1O(CH2)n2(CRaaRbb)mRcc, —(CH2)n1O(CH2)n2Raa, —(CH2)n1S(CH2)n2(CRaaRbb)mRcc, —(CH2)n1O(CH2)n2S(O)mRaa, —(CH2)n1O(CH2)n2S(O)(═NRaa)(CH2)mRbb, —(CH2)n1C(O)Raa, —(CH2)n1C(O)ORaa, —(CH2)n1S(O)mRaa, —(CH2)n1S(O)(═NRa
B · US 2022/0259201 A1 · claim 1
1.10Rc3 and Rc4 are each independently selected from hydrogen, hydroxyl, amino, C1-C5 alkyl, C1-C5 alkoxy, or a 3- to 7-membered ring, or Rc3 and Rc4 are linked together to form a 3- to 7-membered ring
In a further preferred embodiment, when D is one of the above groups, R forms together with the nitrogen, to which it is attached, a heterocyclic ring of group B. More preferably, said heterocyclic ring, which is formed by the NR group, is selected from piperidine, pyrrolidine, tetrahydrofuran, morpholine, piperazine, dioxolane and dioxane.
A · US 11,339,152 B2 · ¶ 127
Raa, Rbb and Rcc, are each independently selected from hydrogen, deuterium, cyano, amino, C1-6 alkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, hydroxyl, C3-8 cycloalkyl, 3-12 membered heterocyclyl or C6-14 aryl, wherein the C1-6 alkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, hydroxyl, C3-8 cycloalkyl, 3-12 membered heterocylcyl and C6-14 aryl are optionally further substituted by one or more substituents selected from hydrogen, halogen, cyano, hydroxyl, oxo, imino, C1-6 alkyl or C1-6 hydroxya
B · US 2022/0259201 A1 · ¶ 132
1.11m and n are each optionally 0, 1, or 2
1.12the alkyl, alkoxy, cycloalkyl, cycloalkoxy, 5- to 7-membered ring, or 3- to 7-membered ring is optionally substituted with one or more deuterium, halogen, hydroxyl, cyano, oxo, C1-C5 alkyl, C1-C5 alkoxy, or amino.
When E represents optionally substituted heteroaryl, examples include pyridinyl (e.g. pyridin-2-yl and pyridin-4-yl) and pyrimidinyl. Specific substituents that may be mentioned are one or more e.g. 1, 2 or 3 groups selected from halogen, hydroxyl, alkyl (e.g. methyl) and alkoxy-(e.g. methoxy-).
A · US 11,339,152 B2 · ¶ 84

An empty cell means only that no passage was reproduced there.

Statements in these documents
Since the formation of pGlu-Aβ-related peptides can be suppressed by inhibition of recombinant human QC and QC-activity from pig pituitary extracts, the enzyme QC is a target in drug development for treatment of Alzheimer's disease.
A · US 11,339,152 B2 · ¶ 6
EP 02 011 349.4 discloses polynucleotides encoding insect glutaminyl cyclase, as well as polypeptides encoded thereby and their use in methods of screening for agents that reduce glutaminyl cyclase activity.
A · US 11,339,152 B2 · ¶ 8
At present, multi-kinase inhibitors (MKI) such as vandetinib and cabozantinib are mostly used in clinical drugs, these multi-kinase inhibitors have the disadvantages of high side effects and poor efficacy due to poor selectivity, and they cannot overcome the drug resistance problems that occur during treatment.
B · US 2022/0259201 A1 · ¶ 5
RET inhibitors with higher selectivity, better activity, better safety, and the ability to overcome drug-resistant mutations have the potential to treat a variety of cancers and have broad market prospects.
B · US 2022/0259201 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0356823 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356823/, SHA-256 13ef34a72a4b83559a274004aea549e5edf1d2a6252db71427f86f3b3674cac9
First published
Permanent addresshttps://patent.fyi/US20260356823/
Content fingerprint (SHA-256)13ef34a72a4b83559a274004aea549e5edf1d2a6252db71427f86f3b3674cac9
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi